Enzolytics Inc. (OTC:ENZC) Stock Surges 12%: What’s the Buzz?

There were a number of companies that had come into the news cycle for one reason or another, and one of those was Enzolytics Inc. (OTC:ENZC). The company came into focus after it announced that it had commenced a cooperative effort with the Department of Immunology of the Bulgarian Academy of Science and the Stephan Angeloff Institute of Microbiology for the expansion of the use of each other’s technologies.

The Department of Immunology boasts of as many as seven advanced laboratory facilities, and the main areas of research for the organization include allergy, cancer, vaccines, immunomodulators, autoimmunity, and autoimmune diseases. The efforts are mainly focused on the development of novel approaches for the suppression of pathological immune cells by way of protein molecules and genetic engineering. In the news release, the company also enumerated the research infrastructure capabilities and the high-scale production capacity for antibodies that were being produced.

The Chief Scientific Officer of Enzolytics, Harry Zhabilov, spoke about the move from the company. He noted that due to the presence of highly prestigious academicians at the Department of Immunology, led by Professor Andrey Tchorbanov, the company would be in a position to boost the potency of its exclusively licensed cancer immunotherapy treatment.

He went on to state that he was hopeful that it may be possible to integrate parts of the portfolio of products and the processes at the department of immunology to further unlock considerable value for the company’s shareholders. The Chief Executive Officer of Enzolytics, Steve Sharabura, stated that it was another illustration of the exciting new initiatives undertaken by the company in its quest to move into new avenues. He concluded by stating that everyone at the company was excited at the possibility of creating a strong enterprise. It could be a good time for investors to add the Enzolytics stock to their watch lists.